Stemline, Leukemia & Lymphoma Society partner for blood cancer drug development

10/30/2013 | Pharmaceutical Business Review Online

The Leukemia & Lymphoma Society is partnering with Stemline Therapeutics to support the development of the experimental drug SL-401 for the treatment of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The Leukemia & Lymphoma Society pledged more than $3 million for the project and will work to increase the awareness of physicians and patients about blastic plasmacytoid dendritic cell neoplasm.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA